Zacks Investment Research upgraded shares of CSPC Pharmaceutical Group Ltd (NASDAQ:CHPTY) from a sell rating to a buy rating in a research note issued to investors on Monday morning. They currently have $82.00 target price on the stock.

According to Zacks, “CSPC Pharmaceutical Group Limited operates as a pharmaceutical group in China. Its bulk drug products include vitamin C, penicillin G and 7-ACA. The Company is also a major manufacturer of antibiotic finished drugs such as penicillin and cephalosporin products. CSPC Pharmaceutical Group Limited, formerly known as China Pharmaceutical Group Limited, is based in Wan Chai, Hong Kong. “

Shares of CSPC Pharmaceutical Group (NASDAQ:CHPTY) traded up 9.24% during mid-day trading on Monday, hitting $80.04. 43 shares of the stock were exchanged. The company has a 50-day moving average price of $77.91 and a 200-day moving average price of $71.74. The stock has a market cap of $9.69 billion and a price-to-earnings ratio of 32.02. CSPC Pharmaceutical Group has a 12 month low of $51.03 and a 12 month high of $80.04.

TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at

About CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).

Get a free copy of the Zacks research report on CSPC Pharmaceutical Group (CHPTY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for CSPC Pharmaceutical Group Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSPC Pharmaceutical Group Ltd and related stocks with our FREE daily email newsletter.